Synthesis and Biological Evaluation of New Nitroimidazole Derivatives as Anti-Helicobacter pylori Agents Against Metronidazole-Resistant Strains

IF 1.8 4区医学 Q3 PHARMACOLOGY & PHARMACY

Iranian Journal of Pharmaceutical Research Pub Date : 2023-10-14 DOI:10.5812/ijpr-137969

Zahra Bayati, Salimeh Amidi, Mahnaz Shahabimehr, Masoud Alebouyeh, Arash Mahboubi, Sayyed Abbas Tabatabai

引用次数: 0

Abstract

: Since several Helicobacter pylori strains have become resistant to metronidazole, new nitroimidazole derivatives based on metronidazole were designed and synthesized with different substituents on imidazole nitrogen. The activity of the synthesized compounds was evaluated against 20 clinically isolated metronidazole-resistant H. pylori strains. Some synthesized compounds were effective against those metronidazole-resistant H. pylori strains. Three compounds exhibited the most potent inhibitory activities (MIC50 = 8 µg/mL and MIC90 = 16 µg/mL).

查看原文本刊更多论文

新型硝基咪唑衍生物抗甲硝唑耐药幽门螺杆菌的合成及生物学评价

:由于一些幽门螺杆菌对甲硝唑产生耐药性，设计并合成了以甲硝唑为基础，在咪唑氮上加入不同取代基的新型硝基咪唑衍生物。对合成的化合物对20株临床分离的耐甲硝唑幽门螺杆菌进行了活性评价。部分合成的化合物对甲硝唑耐药幽门螺杆菌有效。3种化合物的抑菌活性最强(MIC50 = 8µg/mL, MIC90 = 16µg/mL)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Pharmaceutical Research 医学-药学

CiteScore

3.40

自引率

6.20%

发文量

审稿时长

2 months

期刊介绍： The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication, scheduled to appear quarterly and serve as a means for scientific information exchange in the international pharmaceutical forum. Specific scientific topics of interest to the journal include, but are not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy.